Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vir Biotechnology stock in Canada | $44.94

Own Vir Biotechnology shares in just a few minutes.

Vir Biotechnology, Inc
-$0.20 (-0.56%)

Vir Biotechnology is a biotechnology business based in the US. Vir Biotechnology stocks (VIR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $36.39 – an increase of 7.23% over the previous week. Vir Biotechnology employs 340 staff and has a trailing 12-month revenue of around $72.6 million.

How to buy Vir Biotechnology stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: VIR in this case.
  5. Research Vir Biotechnology stocks. The platform should provide the latest information available.
  6. Buy your Vir Biotechnology stocks. It's that simple.

How has Coronavirus impacted Vir Biotechnology's stock price?

Since the stock market crash in March caused by coronavirus, Vir Biotechnology's stock price has had significant positive movement.

Its last market close was $44.94, which is 63.82% up on its pre-crash value of $16.26 and 179.30% up on the lowest point reached during the March crash when the stocks fell as low as $16.09.

If you had bought $1,000 worth of Vir Biotechnology stocks at the start of February 2020, those stocks would have been worth $1,605.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,970.62.

Vir Biotechnology stock price

Use our graph to track the performance of VIR stocks over time.

Vir Biotechnology stocks at a glance

Information last updated 2021-07-28.
Latest market close$44.94
52-week range$25.31 - $83.5
50-day moving average $42.1383
200-day moving average $48.9147
Wall St. target price$81.17
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.76

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Vir Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Vir Biotechnology price performance over time

Historical closes compared with the last close of $44.94

1 month (2021-06-30) -4.95%
3 months (2021-04-30) -5.87%

Vir Biotechnology financials

Revenue TTM USD$72.6 million
Gross profit TTM USD$-196,511,000
Return on assets TTM -25.36%
Return on equity TTM -75.7%
Profit margin 0%
Book value $5.011
Market capitalisation USD$4.8 billion

TTM: trailing 12 months

How to short and sell Vir Biotechnology stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "VIR.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 8.6 million Vir Biotechnology stocks held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 2.3% up from 8.4 million last month.

There are a few different ways that this level of interest in shorting Vir Biotechnology stocks can be evaluated.

Vir Biotechnology's "short interest ratio" (SIR)

Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology stocks currently shorted divided by the average quantity of Vir Biotechnology stocks traded daily (recently around 799774.46610956). Vir Biotechnology's SIR currently stands at 10.77. In other words for every 100,000 Vir Biotechnology stocks traded daily on the market, roughly 10770 stocks are currently held short.

However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology stocks, or, against the total number of tradable Vir Biotechnology stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.07% of the outstanding stocks (for every 100,000 Vir Biotechnology stocks in existence, roughly 70 stocks are currently held short) or 0.1232% of the tradable stocks (for every 100,000 tradable Vir Biotechnology stocks, roughly 123 stocks are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against Vir Biotechnology.

Find out more about how you can short Vir Biotechnology stock.

Vir Biotechnology stock dividends

We're not expecting Vir Biotechnology to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Vir Biotechnology overview

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

Stocks similar to Vir Biotechnology

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site